{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:51:44Z","timestamp":1770972704872,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18783-8","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:04:06Z","timestamp":1764165846000},"page":"2298-2305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Axillary Management in Breast Cancer Patients with Positive Lymph Nodes Following Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"33","author":[{"given":"Vanessa M. S.","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Addie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Roy Pickard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Josey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Benzouak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Villareal-Corpuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipshita","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarkis","family":"Meterissian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"4","key":"18783_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: A review. JAMA Oncol. 2017;3(4):549\u201355. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4163.","journal-title":"JAMA Oncol"},{"key":"18783_CR2","unstructured":"National Comprehensive Cancer Networks Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer, Version 4.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf Accessed July 9 2025"},{"key":"18783_CR3","doi-asserted-by":"publisher","first-page":"117822342098037","DOI":"10.1177\/1178223420980377","volume":"14","author":"M Asaoka","year":"2020","unstructured":"Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant chemotherapy for breast cancer: past, present, and future. Breast Cancer Basic Clin Res. 2020;14:1178223420980377\u20131178223420980377. https:\/\/doi.org\/10.1177\/1178223420980377.","journal-title":"Breast Cancer Basic Clin Res"},{"issue":"1","key":"18783_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/bjs.4840","volume":"92","author":"H Charfare","year":"2005","unstructured":"Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005;92(1):14\u201323.","journal-title":"Br J Surg"},{"issue":"10","key":"18783_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/bjs.5894","volume":"94","author":"JSD Mieog","year":"2007","unstructured":"Mieog JSD, van der Hage JA, van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94(10):1189\u2013200.","journal-title":"Br J Surg"},{"issue":"9","key":"18783_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/14656566.2020.1746273","volume":"21","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Nuzzolese I, Ponzone R. Neoadjuvant or adjuvant chemotherapy in early breast cancer? Exp Opin Pharmacother. 2020;21(9):1071\u201382. https:\/\/doi.org\/10.1080\/14656566.2020.1746273.","journal-title":"Exp Opin Pharmacother"},{"issue":"4","key":"18783_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/SLA.0000000000002373","volume":"266","author":"JC Boughey","year":"2017","unstructured":"Boughey JC, Ballman KV, McCall LM, et al. Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance). Ann Surg. 2017;266(4):667\u201376. https:\/\/doi.org\/10.1097\/SLA.0000000000002373.","journal-title":"Ann Surg"},{"issue":"14","key":"18783_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA."},{"issue":"3","key":"18783_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"J-F Boileau","year":"2015","unstructured":"Boileau J-F, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol"},{"key":"18783_CR10","doi-asserted-by":"crossref","unstructured":"Boughey J, Suman V, Hunt KJ, et al. Abstract RF2-01: Factors influencing additional nodal disease and pathologic nodal upstaging with axillary dissection in patients with residual node-positive breast cancer after neoadjuvant chemotherapy enrolled on Alliance A011202 Clinical Trial. Clinical Cancer Res. 2025;31(12_Supplement):RF2-01. Abstract","DOI":"10.1158\/1557-3265.SABCS24-RF2-01"},{"issue":"11","key":"18783_CR11","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Almana N, Choi J, et al. Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2019;26(11):3502\u20139. https:\/\/doi.org\/10.1245\/s10434-019-07517-2.","journal-title":"Ann Surg Oncol"},{"key":"18783_CR12","doi-asserted-by":"crossref","unstructured":"Brackstone MA-O, Baldassarre FG, Perera FE, et al. Management of the axilla in early-stage breast cancer. Toronto (ON): Ontario Health (Cancer Care Ontario). 2021","DOI":"10.1200\/JCO.21.00934"},{"issue":"4","key":"18783_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):606\u20138. https:\/\/doi.org\/10.1097\/SLA.0000000000000924.","journal-title":"Ann Surg."},{"key":"18783_CR14","doi-asserted-by":"publisher","unstructured":"Kuehn T, Bauerfeind I Fau-Fehm T, Fehm T Fau-Fleige B, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609-18. https:\/\/doi.org\/10.1016\/S1470-2045(13)70136-9","DOI":"10.1016\/S1470-2045(13)70136-9"},{"key":"18783_CR15","doi-asserted-by":"publisher","unstructured":"Classe JA-O, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Ann Oncol. 2019;30(6):974-80. https:\/\/doi.org\/10.1093\/annonc\/mdz108","DOI":"10.1093\/annonc\/mdz108"},{"issue":"10","key":"18783_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"J Clin Oncol"},{"issue":"11","key":"18783_CR17","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.1245\/s10434-024-15797-6","volume":"31","author":"AM Moore","year":"2024","unstructured":"Moore AM, Caudle AS, Sun SX, et al. Residual nodal burden after neoadjuvant chemotherapy in cn1 breast cancer patients with positive nodes at targeted axillary dissection. Ann Surg Oncol. 2024;31(11):7264\u201370. https:\/\/doi.org\/10.1245\/s10434-024-15797-6.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"18783_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-022-06677-2","volume":"195","author":"A Weiss","year":"2022","unstructured":"Weiss A, King C, Vincuilla J, et al. Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy. Breast Cancer Res Treat. 2022;195(2):181\u20139. https:\/\/doi.org\/10.1007\/s10549-022-06677-2.","journal-title":"Breast Cancer Res Treat"},{"key":"18783_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.radonc.2021.08.013","volume":"163","author":"MC Leonardi","year":"2021","unstructured":"Leonardi MC, Arrobbio C, Gandini S, et al. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. Radiother Oncol. 2021;163:128\u201335. https:\/\/doi.org\/10.1016\/j.radonc.2021.08.013.","journal-title":"Radiother Oncol"},{"key":"18783_CR20","doi-asserted-by":"crossref","unstructured":"Jeruss JS, Newman La Fau - Ayers GD, Ayers Gd Fau - Cristofanilli M, et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer. 2008;112(12):2646-54.","DOI":"10.1002\/cncr.23481"},{"issue":"5","key":"18783_CR21","first-page":"e407","volume":"21","author":"AU Barron","year":"2021","unstructured":"Barron AU, Hoskin TL, Boughey JC. Predicting non-sentinel lymph node metastases in patients with a positive sentinel lymph node after neoadjuvant chemotherapy. Clin Breast Cancer. 2021;21(5):e407\u201315.","journal-title":"Clin Breast Cancer"},{"key":"18783_CR22","unstructured":"Song SA-O, Cho KA-O, Cho YA-O, et al. Value of breast MRI and nomogram after negative axillary ultrasound for predicting axillary lymph node metastasis in patients with clinically T1-2 N0 breast cancer. Cancer Res Treat. 2014;46(4):343-9."},{"issue":"3","key":"18783_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/radiol.2020192534","volume":"295","author":"JM Chang","year":"2020","unstructured":"Chang JM, Leung JWT, Moy L, Ha SM, Moon WK. Axillary nodal evaluation in breast cancer: State of the art. Radiology. 2020;295(3):500\u201315. https:\/\/doi.org\/10.1148\/radiol.2020192534.","journal-title":"Radiology"},{"key":"18783_CR24","doi-asserted-by":"crossref","unstructured":"Marino MA-O, Avendano D, Zapata P, Riedl CC, Pinker KA-O. Lymph node imaging in patients with primary breast cancer: Concurrent diagnostic tools. Oncologist. 2020;25(2):e231-40.","DOI":"10.1634\/theoncologist.2019-0427"},{"issue":"1","key":"18783_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12893-024-02500-5","volume":"24","author":"L Yilmaz","year":"2024","unstructured":"Yilmaz L, Kus T, Aytekin A, Aktas G, Uzun E, Maralcan G. Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy. BMC Surg. 2024;24(1):213. https:\/\/doi.org\/10.1186\/s12893-024-02500-5.","journal-title":"BMC Surg"},{"issue":"7","key":"18783_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.clbc.2017.03.014","volume":"17","author":"JM Ryu","year":"2017","unstructured":"Ryu JM, Lee SK, Kim JY, et al. Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy: nomogram for predicting nonsentinel lymph node metastasis. Clin Breast Cancer. 2017;17(7):550\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2017.03.014.","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"18783_CR27","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","volume":"25","author":"T-A Moo","year":"2018","unstructured":"Moo T-A, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;25(6):1488\u201394. https:\/\/doi.org\/10.1245\/s10434-018-6429-2.","journal-title":"Ann Surg Oncol"},{"key":"18783_CR28","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, G\u00f3mez-Valles FO, Ram\u00edrez-Valdespino CA. Subtypes of breast cancer. Breast Cancer. 2025."},{"issue":"2","key":"18783_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/annonc\/mds485","volume":"24","author":"I Vaz-Luis","year":"2013","unstructured":"Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol. 2013;24(2):283\u201390. https:\/\/doi.org\/10.1093\/annonc\/mds485.","journal-title":"Ann Oncol"},{"key":"18783_CR30","unstructured":"Institute NC. SEER Cancer Stat Facts: Female Breast Cancer Subtypes. SEER (Surveillance, Epidemiology, and End Results) Program. Updated 2022. Accessed July 10, 2025."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18783-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:39:58Z","timestamp":1770899998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18783-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18783"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18783-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SMW reports advisory roles (steering committees) with Merck and AstraZeneca, outside of the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}